1204例冠状动脉支架血栓患者的抗血小板治疗情况和预后分析

摘要

目的:分析冠状动脉(冠脉)造影证实的支架血栓患者的临床特点、抗血小板治疗和预后.方法:纳入北京安贞医院2008-01-01至2016-12-31期间冠脉造影证实的支架血栓患者1 204例,比较急性支架血栓组(<24小时,n=106)、亚急性支架血栓组(24小时~30天,n=206)、晚发支架血栓组(＞30天~1年,n=268)、极晚发支架血栓组(＞1年,n=624)患者的临床特点、抗血小板治疗情况和预后.结果:急性支架血栓组的左前降支发生支架血栓的比例(51.9%)最高.而极晚发支架血栓组中,左心室射血分数<50%(28.2%)及糖尿病患者的比例(34.1%)较高.在确诊支架血栓时,急性支架血栓组均在应用双联抗血小板治疗,96.5%亚急性支架血栓和94.5%晚发支架血栓患者正在使用双联或三联抗血小板治疗;95.2%的极晚发支架血栓患者服用双联抗血小板治疗或单用抗血小板药物.随访期间,四组患者的死亡率分别高达23.6%、26.7%、26.3%和18.9%.结论:绝大多数冠脉支架血栓患者都在接受规范的抗血小板药物治疗,发生支架血栓患者的预后较差.%Objectives: To describe the differences between patients with angiography confirmed stent thrombosis in antiplatelet therapy and long term outcomes. Methods: We analyzed data from 1 204 patients with angiography – documented stent thrombosis between January 2008 to December 2016 in Beijing Anzhen Hospital. According to the timing of stent thrombosis post stent implantation, patients were divided into acute stent thrombosis (<24 h, n=106), subacute stent thrombosis(24 h~30 d, n=206), late stent thrombosis (>30 d~1y, n=268), and very late stent thrombosis (>1 y, n=624) groups. Death, recurrent stent thrombosis, recurrent myocardial infarction, target vessel revascularization, stroke and antiplatelet treatment during In-hospital or long-term clinical follow-up were compared among groups. Results: Prevalence of stent thrombosis was the highest in the left anterior descending artery (51.9%) in acute stent thrombosis group. Subjects with subacute stent thrombosis had a higher prevalence rate of LVEF<50% (28.2%), and subjects with very late stent thrombosis had a higher prevalence rate of diabetes (34.1%). All patients in acute stent thrombosis group received aspirin + clopidogrel, 96.5% patients in subacute stent thrombosis group and 94.5% patients in late stent thrombosis group were treated with double or triple antiplatelet therapy, while 95.2% patients in the very late stent thrombosis group were treated with double or mono antiplatelet therapy. During the follow up, mortality was 23.6%, 26.7%, 26.3% and 18.9% in acute stent thrombosis, subacute stent thrombosis, late stent thrombosis, and very late stent thrombosis groups, respectively. Conclusions: Most patients with angiography–documented stent thrombosis are treated with recommended antiplatelet therapy. Development of stent thrombosis is associated with poor outcomes.